
Press Release Website

leadXpro and Alipheron are combining their cutting-edge technologies to bring a new level of innovation to early drug discovery.



- By applying intelligent algorithms to detect new drugs in trillions of molecules
- By using high-tech Cryo-EM to elucidate structures of membrane bound proteins
- By accelerating structure-based lead discovery to address unmet medical needs

Villigen and Dornach, Switzerland 3rd September 2024: *leadXpro*, specialized in modern structure-based lead discovery in membrane proteins, and *Alipheron AG*, a provider of innovative software solutions for drug discovery informatics, are pleased to announce a strategic collaboration aimed at accelerating the drug discovery process. This partnership combines leadXpro's extensive expertise in structural biology with Alipheron's innovative software suite for virtual screening of ultra large combinatorial libraries.

«We are excited to partner with Alipheron, whose state-of-the-art informatics solutions will significantly complement our modern lead discovery approach," said **Luboš Remeň**, Director of Lead Medicinal Chemistry at leadXpro. "This collaboration will allow us to leverage our strengths in structural biology and virtual screening, ultimately speeding up the discovery of new molecules and accelerate the development of new and effective therapeutics.»

«Partnering with leadXpro aligns perfectly with our mission to provide superior software that drives scientific innovation," said **Modest von Korff**, CEO of Alipheron. "Our software platform, which includes 3D pharmacophore screening, substructure search,

and high-throughput docking of ultra-large combinatorial libraries containing trillions of molecules, will be combined with leadXpro's structural biology and lead discovery capabilities.»

The goal of the collaboration is to develop a protein-structure-driven virtual screening approach on ultra-large combinatorial libraries as an alternative to classical high-throughput screening (HTS) in drug discovery. This groundbreaking approach represents a significant step forward in the shared goal of both companies to improve human health through innovative drug discovery.

About Alipheron AG

Alipheron provides cutting edge software solutions for cheminformatics.

Our products spans the whole bandwidth of chemical structure and reactions: storage, searching, visualization, prediction.

About leadXpro AG

leadXpro AG is a biotechnology company specialized in structure-based drug discovery for membrane proteins. Membrane proteins are the most promising targets for drug discovery, yet also the most challenging. To unlock these targets, we bring together specialized knowledge in protein science, pioneering technologies in structural biology and expertise in ligand design and characterization. leadXpro's research covers a range of membrane proteins, including GPCRs, ion channels, transporters, and enzymes. leadXpro acts as a research partner for a growing number of pharmaceutical, biotechnology and academic partners.

Media Inquiries

leadXpro AG

Luboš Remeň, Director of Lead Discovery lubos.remen@leadxpro.com
+41 774 981 596
www.leadxpro.com

Alipheron AG

Modest von Korff, CEO Alipheron modest.korff@alipheron.com +49 162 622 4339 www.alipheron.com